1. Home
  2. JYNT vs MOLN Comparison

JYNT vs MOLN Comparison

Compare JYNT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • MOLN
  • Stock Information
  • Founded
  • JYNT 2010
  • MOLN 2004
  • Country
  • JYNT United States
  • MOLN Switzerland
  • Employees
  • JYNT N/A
  • MOLN N/A
  • Industry
  • JYNT Multi-Sector Companies
  • MOLN
  • Sector
  • JYNT Miscellaneous
  • MOLN
  • Exchange
  • JYNT Nasdaq
  • MOLN Nasdaq
  • Market Cap
  • JYNT 149.5M
  • MOLN 139.5M
  • IPO Year
  • JYNT 2014
  • MOLN 2021
  • Fundamental
  • Price
  • JYNT $8.23
  • MOLN $3.92
  • Analyst Decision
  • JYNT Strong Buy
  • MOLN Hold
  • Analyst Count
  • JYNT 3
  • MOLN 1
  • Target Price
  • JYNT $16.33
  • MOLN $4.00
  • AVG Volume (30 Days)
  • JYNT 103.8K
  • MOLN 2.5K
  • Earning Date
  • JYNT 11-06-2025
  • MOLN 11-05-2025
  • Dividend Yield
  • JYNT N/A
  • MOLN N/A
  • EPS Growth
  • JYNT N/A
  • MOLN N/A
  • EPS
  • JYNT N/A
  • MOLN N/A
  • Revenue
  • JYNT $53,449,713.00
  • MOLN $856,302.00
  • Revenue This Year
  • JYNT $7.70
  • MOLN N/A
  • Revenue Next Year
  • JYNT $10.24
  • MOLN $1,000.00
  • P/E Ratio
  • JYNT N/A
  • MOLN N/A
  • Revenue Growth
  • JYNT 277.36
  • MOLN N/A
  • 52 Week Low
  • JYNT $8.01
  • MOLN $3.36
  • 52 Week High
  • JYNT $13.47
  • MOLN $7.60
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 26.97
  • MOLN 56.78
  • Support Level
  • JYNT $8.16
  • MOLN $3.70
  • Resistance Level
  • JYNT $8.60
  • MOLN $3.81
  • Average True Range (ATR)
  • JYNT 0.33
  • MOLN 0.09
  • MACD
  • JYNT -0.04
  • MOLN 0.01
  • Stochastic Oscillator
  • JYNT 12.39
  • MOLN 79.97

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: